Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Buy
57
MAC Quote, Financials, Valuation and Earnings
Last price:
$15.88
Seasonality move
:
1.24%
Day range:
$15.87 - $16.13
52-week range:
$12.48 - $22.27
Dividend yield:
4.24%
P/E ratio:
50.89x
P/S ratio:
3.86x
P/B ratio:
1.52x
Volume:
1.7M
Avg. volume:
2.3M
1-year change:
-0.25%
Market cap:
$4.1B
Revenue:
$918.2M
EPS (TTM):
-$0.43
Analysts' Opinion
-
Consensus RatingMacerich has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.76, Macerich has an estimated upside of 17.06% from its current price of $16.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.70 representing 100% downside risk from its current price of $16.03.
Fair Value
-
According to the consensus of 11 analysts, Macerich has 17.06% upside to fair value with a price target of $18.76 per share.
MAC vs. S&P 500
-
Over the past 5 trading days, Macerich has overperformed the S&P 500 by 1.65% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Macerich does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Macerich has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Macerich reported revenues of $249.2M.
Earnings Growth
-
Macerich has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Macerich reported earnings per share of -$0.20.
Enterprise value:
9.1B
EV / Invested capital:
1.14x
Price / LTM sales:
3.86x
EV / EBIT:
31.10x
EV / Revenue:
9.51x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
29.32x
Price / Operating cash flow:
11.92x
Enterprise value / EBITDA:
14.64x
Gross Profit (TTM):
$515.1M
Return On Assets:
-1.47%
Net Income Margin (TTM):
-12.26%
Return On Equity:
-4.48%
Return On Invested Capital:
-1.61%
Operating Margin:
12.79%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $857.9M | $878M | $958.6M | $208.8M | $249.2M | |
| Gross Profit | $466M | $478.2M | $515.1M | $104.9M | $132.1M | |
| Operating Income | $148.5M | $169.1M | $168M | $28.9M | $31.9M | |
| EBITDA | $394.7M | $72.5M | $622.8M | -$9.1M | $112.3M | |
| Diluted EPS | -$0.40 | -$1.59 | -$0.43 | -$0.59 | -$0.20 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4B | $348M | $374.4M | $372.5M | $474.8M | |
| Total Assets | $9.7B | $8.2B | $7.9B | $7.4B | $8.7B | |
| Current Liabilities | $436.5M | $405.5M | $563.4M | $546.1M | $638.4M | |
| Total Liabilities | $6.7B | $5.1B | $5.1B | $5B | $5.9B | |
| Total Equity | $3B | $3.1B | $2.9B | $2.4B | $2.7B | |
| Total Debt | $6B | $4.5B | $4.3B | $4.3B | $5.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $352.8M | $275.9M | $310.8M | $61.1M | $88.5M | |
| Cash From Investing | $69.8M | -$92.6M | -$36.3M | -$27M | -$83M | |
| Cash From Financing | -$401.1M | -$163.9M | -$155.1M | $667K | $161.6M | |
| Free Cash Flow | $352.8M | $275.9M | $310.8M | $61.1M | $88.5M | |
MAC
Sector
Market Cap
$4.1B
$1.1B
Price % of 52-Week High
71.98%
82.05%
Dividend Yield
4.24%
3.27%
Shareholder Yield
--
4.07%
1-Year Price Total Return
-0.25%
-0.29%
Beta (5-Year)
2.143
0.775
Dividend yield:
4.24%
Annualized payout:
$0.68
Payout ratio:
-146.81%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$15.63
200-day SMA
Sell
Level
$17.83
Bollinger Bands (100)
Sell
Level
15.45 - 20.29
Chaikin Money Flow
Buy
Level
76M
20-day SMA
Buy
Level
$15.07
Relative Strength Index (RSI14)
Buy
Level
56.44
ADX Line
Buy
Level
26.54
Williams %R
Neutral
Level
-39.8714
50-day SMA
Buy
Level
$15.69
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
167.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.041)
Sell
CA Score
(Annual)
Level (-1.2192)
Buy
Beneish M-Score
(Annual)
Level (-2.8326)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (1.2446)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Macerich invests in premium mall assets. The company owns 30 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.9 million square feet of gross leasable area and averaged $837 sales per square foot over the 12 months ended in December 2024.
Stock Forecast FAQ
In the current month, MAC has received 3 Buy ratings 8 Hold ratings, and 0 Sell ratings. The MAC average analyst price target in the past 3 months is $18.76.
-
Where Will Macerich Stock Be In 1 Year?
According to analysts, the consensus estimate is that Macerich share price will rise to $18.76 per share over the next 12 months.
-
What Do Analysts Say About Macerich?
Analysts are divided on their view about Macerich share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Macerich is a Sell and believe this share price will drop from its current level to $13.70.
-
What Is Macerich's Price Target?
The price target for Macerich over the next 1-year time period is forecast to be $18.76 according to 11 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is MAC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Macerich is a Hold. 8 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MAC?
You can purchase shares of Macerich via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Macerich shares.
-
What Is The Macerich Share Price Today?
Macerich was last trading at $15.88 per share. This represents the most recent stock quote for Macerich. Yesterday, Macerich closed at $16.03 per share.
-
How To Buy Macerich Stock Online?
In order to purchase Macerich stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
81
SMLR alert for May 19
Semler Scientific [SMLR] is up 5.85% over the past day.
Sell
25
GLOB alert for May 19
Globant SA [GLOB] is up 4.02% over the past day.
Buy
94
HIMS alert for May 19
Hims & Hers Health [HIMS] is down 3.57% over the past day.
